Monica Heyl and Associates, LLC: Providing Field Analytical Solutions
Steven Michael Jones, Ph.D.

Steven Michael Jones, Ph.D.

Senior Science Officer - Director - Programme Manager - Scientist/Researcher

Public Health Security - Molecular Research & Diagnostics Organizations

Career Profile and Distinctions:

  • Dynamic, entrepreneurial business professional with high-calibre general management qualifications... strong orientations in finance and technology... proven leadership talents. Led the development of the counter terrorism program for the Public Health Agency of Canada and turned around an existing test/surveillance laboratory.
  • Accomplished senior-level scientist and recognized innovator in modern technical and managerial strategies, principles, methodologies and processes for the biotech industry and Public Health Sector. Designed and developed numerous scientifically/commercially significant diagnostic reagents and assays.
  • Professional experience spanning diverse clinical and technical settings, private biotech health organizations ... hospitals ... academic organisations ... large R&D operations ... public facilities ... national security projects.
  • Accustomed to, and effective in high-profile scientist executive roles ... managing large organizations ... overcoming complex business/technical challenges ... gaining respect from competitors and peers ... communicating complex concepts to technical and non-technical audiences... maintaining impartiality in politically charged environments ... fostering consensus and generating cooperation from multicultural, multidisciplinary teams.
  • Confident, assertive, diplomatic and outgoing with exceptional communication, public speaking and interpersonal relations skills. Highly experienced working in complex multicultural environments from the Americas, Europe, Africa and Asia.

Back To Top

Management Qualifications:

  • Entrepreneurial Vision, Strategy & Leadership
  • Operations Management
  • Financial Planning & Management
  • Budget Planning, Analysis & Control
  • Programme & Project Management
  • Process Design/improvement - Business & Technical
  • Staff Training, Development & Supervision
  • Team Building, Mentoring & Leadership
  • Technology investments & Solutions
  • Marketing, Communications & Public Relations

Back To Top

Areas of Expertise

  • National Security Strategies, Policies & Programmes
  • Molecular Diagnostics R&D
  • Immunology & MCM R&D
  • Regulatory Affairs & Compliance GLP/GMP
  • Molecular-Based Surveillance
  • Disease Outbreak investigation & Management
  • Microbial Forensics
  • Laboratory Management Quality improvement & Assurance ISO17025 and ISO9001
  • Emergency Preparedness & Response
  • Field Diagnostics & Mobile Laboratories
  • Advanced Laboratory Procedures & Technologies
  • Training and Evaluation of Responders

Back To Top

Professional Experience:

2010 - Present: President and CEO of Cognoveritas Consulting.

  • Established a newly incorporated consultancy working with federal, international and commercial clients to solve today's most challenging public health issues.
  • More than 15 years hands on experience working with BSL 3 and BSL4 agents both in conventional laboratories and in highly mobile laboratories deployed all over the world. If you have a question about Biosecuirty, Public Health Emergency Preparedness, Management and Response we can support you. We provide expertise in working in high level containment laboratories, mobile laboratory construction and operation, medical countermeasures and assay development for public health threat agents.

Back To Top

2001 - 2010: Microbiologist for Public Health Agency of Canada

  • Held full P&L accountability for the Emerging Bacterial Diseases public health reference laboratory and Microbiological Emergency Response Teams - infectious disease testing and surveillance services, bio-terrorism detection, prevention and response.
  • Managed all aspects of business operations (e.g., strategic planning, budgeting, financial reporting, staffing, workflow, administrative affairs, internal/external customer service, quality, regulatory reporting/affairs).
  • Provided technical and managerial oversight to 7 primary areas of laboratory operations: test development, Assay validation and quality control, disease surveillance, disease outbreak investigations (including emerging infections, international response activities, mobile laboratory capability) Canadian Laboratory Response Network, Immuno-pathology of Viral Haemorrhagic fever viruses, Vaccine design and development and testing for bio-threat organisms/bio-terrorism.
  • Managed $5M annual budget for operations (2010).
  • Lead a three-person management team and provide indirect supervision to seven technical and non-technical support employees and students.
  • Attracted $38Million in additional funding between 2002 and 2010 and provided program and project management for these funds.
  • Provided National Strategic and Policy in the Academic Sector through membership of the Canadian Institutes of Health Research; Institute Advisory Board for Infection and Immunity and for the Federal Government Public Security Technical Program through membership in the Program Management Board and by Leading the Biological Science Cluster.
  • Developed and assessed Training Activities and Exercises from full-scale national exercises to interactive electronic table-top exercises.

Back To Top

2010: Director of Bioterrorism Response and Biosecurity for the Vancouver 2010 Olympic and Paralympic games and the G8/G20 Summits

  • Management & Leadership Successes:
    • Used strong strategic planning management style to train and supervise multidisciplinary teams of up to 30 people.
    • Orchestrated the biological security operations at all venues for the Games and Summit. This required managing the daily operations of teams a hundred miles away.
    • Constantly met and exceeded organizational goals and deadlines.
    • Managed the design, development, construction and introduction of a $2 Million mobile laboratory capability to support Olympic operations.
    • Orchestrated the development and installation of a novel $1Million environmental microbiological air sampling capability at both the Olympic Games and G8/20 Summits.
    • Integrated laboratory support with law enforcement, security and public safety across governmental, cultural and organizational boundaries.
    • Was the key advisor to policy makers in local, provincial and federal government.
    • Was the Bio-security advisor to the Privy Council Directorate of V2010 and G8 Security.
    • Developed and implemented the support plan for the Public Health Agency of Canada Microbiological Response teams at the Games and G8/20 Summits.
    • Was the Special Advisor to the World Health Organization for Counter terrorism and Public Health Security at the Shanghai World EXPO 2010 and ASIAN Games in Guangdong, Guangzhou, 2010.
    • Assisted Chinese Public Health Laboratories in Shanghai and Guangdong in preparing for possible public health security threats associated with mass gathering events.
    • Was the Head of Delegation of the AUS/CAN/UK/US Technical Support Working Group.
  • Clinical Projects & Achievements
    • Was the distinguished and top-ranking science officer providing consulting, advisory and leadership services on matters related to molecular diagnostics pathology and immunology of emerging/re-emerging diseases.
    • Led the diagnostic teams during the Vancouver Olympic and Paralympic Games, this team performed over 40,000 PCR and RT-PCR tests in only 8 week working in mobile truck based laboratories.
    • Led the entire development cycle - design, validation, application, training, troubleshooting of molecular diagnostics-based assays for rapid investigation, diagnosis and surveillance of emerging/re-emerging infectious diseases including Anthrax, Plague, Tularemia, Brucella, Melliodosis, Glanders, Q Fever, Clostridium botulinum bacterial and toxin specific PCR, 5 species of Ebola virus, Marburg virus, Lassa fever CCHF virus, South American Arena viruses, waterborne and food borne terrorism threat agents. In total, more the 30 multiplexed assays were developed.
    • Participated in validation of new rapid tests developed by CDC for BT organisms and the emerging virus pathogens.
    • Facilitated two international scientific Workshops for the Global Health Security Action Group.

Back To Top

2005 - 2010 Head of Emerging Bacterial Diseases

Was a key member of the senior management team at the Canadian National Microbiology Laboratory reporting directly to the Scientific Director General for all BT and emerging disease related issues. Led a multidisciplinary team and responsible for all budgetary and technical planning. Supervised 10 biologists, technicians and students.

  • Management Achievements:
    • Distinguished the facility as one of the best labs in North America, and one of the first public health organizations to receive government funding for bio-terrorism testing and preparedness.
    • Evolved a very basic laboratory operation into a dynamic scientific organization staffed with talented, highly trained professionals using state-of-the-art technologies and contemporary methodologies to perform sophisticated testing/surveillance of emerging infections.
    • Led an ambitious campaign to secure millions of dollars in investment in technology (government sources). Achieved financial accountability and discipline throughout the organization in order to maximize ROl.
    • Equipped the organization and prepared the staff to handle both routine and emerging infections (including potential bio-terrorism organisms) despite the challenges of operating under serious financial and staff constraints.
    • Designed and led intensive training and career development programmes - trained/qualified four professionals in advanced molecular testing - and provided team coaching and one-to-one mentoring.
    • Designed and implemented training courses for National CBRNE Response Team partners and national first responders.
    • Was a creative presenter, facilitator and coach with strong communication and interpersonal skills.
    • Proven ability to use innovative delivery methods and group dynamics to improve the quality of the training experience.
    • Served as an effective representative/spokesperson for the organization to internal and external parties - scientific community, government agencies, regulatory officials, media, and the public - and continue to advocate on behalf of the laboratory and its activities, budgets, personnel and projects.
    • Was the WHO Special Technical Advisor on bioterrorism and high containment microbiology for the 2008 Beijing Olympic Games. Provided Training to Chinese CDC staff and managed a mobile diagnostic laboratory in Beijing for four weeks before and during the Olympic Games.
    • Established the Canadian Laboratory Response Network in two years after previous attempts had failed over the preceding 8 years.
  • Clinical Projects & Achievements:
    • Used results focused approach and introduced novel technologies to reduce diagnostic turn around times from > 3 months to 24 hours for preliminary result and confirmed laboratory analysis within 5 working days.
    • Introduced ISO 17025 accredited diagnostic procedures without impacting performance or increasing staffing or funding.
    • Pioneered the deployment of laboratory.
    • Led the development of a standard protocol for accrediting new molecular and immunological assays for biological threat agents and emerging diseases.
    • Developed the only microbial forensics facility in Canada using ISO17025 accredited testing.
    • Led the development of a novel Laboratory Information Management System that tracks all samples and results enforcing chain of custody procedures on all laboratory staff.
    • Senior Scientist for the National CBRNE Response Team and commands the bio-terrorism response as well as providing advice and guidance to the commanding officers of the Army and RCMP teams.

Back To Top

2001 - 2010 Head of Immunopathology

  • Management Achievements:
    • Developed the Immunopathology team from one Research Scientist and technician to a team of more than 10 people using funding from external sources.
    • Managed a therapeutic antibody project involving two Federal Government Laboratories, a University and an Industrial partner.
    • Secured funding for a 5-year vaccine development project leading to GMP stocks of vaccine for emergency use by the Public Health Agency of Canada.
    • Field Laboratory Director WHO/GOARN Marburg Outbreak Angola The lab performed PCR based diagnostic testing for Marburg virus infection in patients and the recently deceased additionally the Lab ran PCR for Malaria to exclude the most common alternative agent in the differential diagnosis. The Laboratory team also assisted the outbreak response by taking samples in the field and providing expert advice to the medical teams in the hospital isolation wards.
    • Negotiated licensing deal with a commercial partner to develop the Ebola Virus Vaccine.
    • Was the government spokesman for 1918 Influenza studies, appeared on National News and The Daily Planet.
    • Was an organising committee member of Filoviruses: Recent Advances and Future Challenges Symposium. September 17, 18 and 19 2006, Winnipeg, Manitoba, Canada.
  • Projects & Achievements:
    • Developed highly innovative vaccines for Ebola, Marburg and Lassa virus using live recombinant virus vectors.
    • Investigated the role of the immune system in the pathogenesis of these infections. Of particular interest is the interface between the innate and adaptive immune response and currently we are investigating the roles of different dendritic cell subsets in pathogenesis and protection during viral hemorrhagic fever infection.
    • Developed new and improved animal models using knockout mutant mouse models.
    • Led a multidisciplinary team conducting the most complete study on the use of nonhuman primates as animal models for testing vaccines for SARS coronavirus.
    • Demonstrated that neutralizing monoclonal antibodies can be administered systemically to mice and that subsequent mucosal infection is significantly reduced.
    • Played a leading role in the Canadian diagnostic and research response to the 2003 SARS epidemic in Canada. The special pathogens program developed molecular and serological diagnostic tests for the SARS coronavirus and was responsible for running these tests on over 14,000 clinical samples.
    • Planned and led the team conducting experiments investigating the basis for pathogenesis of the 1918 Spanish Influenza Outbreak in Nonhuman Primates.
    • Featured in CBC documentary "The Virus Hunters".
    • Was a reviewer for The Lancet 2004 1 paper, Archives of Virology 2003-2006 5 papers, Emerging Infectious Diseases 2005 1 paper, Viral Immunology 2003 1 paper The Lancet Infectious Diseases 2005.
    • Has been a member of Manitoba Health research council Review panel for operating and establishment grants since 2004.

Back To Top

2000 - 2001 Scientific Leader - Cellular Immunology Group
Defence Science and Technology Laboratories
Porton Down, Salisbury, United Kingdom

  • Management Achievements:
    • Led a team of 5 scientists and technicians, providing immunological expertise to multidisciplinary teams developing vaccines and immunotherapies.
    • Was the immunology flow cytometry facility manager and provided training and technical advice to other workers.
    • Managed an ISO9001 Accredited laboratory.
    • Was responsible for the use of radioactive reagents within the Microbiology Department as Departmental radiological protection supervisor.
    • Led a team of Scientists and technical staff working on a GLP study as the deputy study director for the GLP Plague vaccine program.
    • Responsible for the safety and quality management within the GLP ADCP Cat III laboratories.
    • Awarded the DSTL Fellowship for outstanding research potential 3 years funding.
    • Sought and was awarded funding for two 3 year strategic research projects worth $5Million.
  • Projects & Achievements:
    • Developed and applied assays for cell-mediated immunity in animals infected with a wide range of containment level III pathogens.
    • Was responsible for investigating the immune responses to novel live vaccine vectors including Salmonella typhimurium and S. typhi, vaccinia virus and adenovirus.
    • Developed a novel immunization technique using antigen pulsed dendritic cells to protect against infection and identify immunogenic peptides by sequencing the peptide presented by MHC molecules on the dendritic cell.
    • Held a Home Office Animal Experimental License for 8 years.
    • Developed immunologically relevant animal models for a number of pathogens including Burkholderia mallei, B. pseudomallei, Yersinia pestis and Francisella tularensis and established immune correlates of protection.
    • Investigated antigen specific T-cell memory responses in non-human primates and humans including specific cytokine production by T-cells as part of the pre-clinical/clinical trials of the recombinant plague and anthrax vaccines.

Back To Top

1997 - 2000 Post Doctoral Research - CBD Porton Down

  • Researched on a subunit vaccine that protects against Bubonic and Pneumonic Plague. Research included the mechanism of protection and the host response to infection, particularly the inflammatory response.
  • Was a member of many multidisciplinary teams. Worked with bacteriologists, molecular biologists and virologists as an expert immunologist.
  • Established the Flow Cytometry capability using the Coulter EPICS XL-MCL and Beckton Dickinson FACScan to study immune responses and infections in humans, mice and non-human primates.
  • Mentored a sandwich student to develop assays to investigate the role of antibodies, cytokines and lymphocytes in the immune response. These include ELISA, ELISPOT, and T-cell proliferation.

Back To Top

Education:

  • Ph.D. - University of Plymouth, United Kingdom, 1997
  • B.Sc. (Hons) 1st - Class University of Plymouth, United Kingdom 1992

Back To Top

Selected Publications
A small selection of peer reviewed publications from a list of over 240 technical papers operation procedures and presentations.

  • Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. Bente DA, Alimonti JB, Shieh WJ, Camus G, Ströher U, Zaki S, Jones SM. J Virol. 2010 Nov;84(21):11089-100. Epub 2010 Aug 25.
  • Factors Associated with Marburg Hemorrhagic Fever: Analysis of Patient Data from Uige, Angola. Roddy P, Thomas SL, Jeffs B, Nascimento Folo P, Pablo Palma P, Moco Henrique B, Villa L, Damiao Machado FP, Bernal O, Jones SM, Strong JE, Feldmann H, Borchert M. J Infect Dis. 2010
  • Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Ströher U, Feldmann H, Jones SM. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS ONE. 2009;4(5):e5547. Epub 2009 May 14.
  • Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, Hensley LE, Feldmann H, Jones SM. Recombinant vesicular stomatitis virus vector mediates post exposure protection against Sudan ebola hemorrhagic fever in nonhuman primates.J Virol. 2008 Jun;82(11):5664-8
  • Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, Fritz EA, Fernando L, Kagan E, Jahrling PB, Hensley LE, Jones SM, Feldmann H. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet. 2006 Apr 29;367(9520):1399-404.
  • Geisbert TW*, Jones S*, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Stroher U, Fernando L, Daddario KM, Guttieri MC, Mothe BR, Larsen T, Hensley LE, Jahrling PB, Feldmann H. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005 Jun;2(6):e183
  • Jones SM*, Feldmann H*, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005 Jul;11(7):786-90.
  • Williamson ED, Flick-Smith HC, LeButt C, Rowland CA, Jones SM, Waters EL, Gwyther RJ, Miller J, Packer PJ, Irving M. Human immune correlates predictive of protection against plague. Infection and Immunity, 2005 Jun;73(6):3598-608

Back To Top

Professional Affiliations:

  • American Society of Microbiology
  • Canadian Association for Clinical Microbiology and Infectious Diseases

Back To Top

Dr. Jones is a named inventor on 4 pending patent applications:

  1. Live replicating virus vectors for viral haemorrhagic fever agents
  2. SARS coronavirus specific antibodies
  3. SARS coronavirus genome
  4. Protective monoclonal antibodies to Ebola and Marburg viruses

Back To Top